BCIQ Profiles

Company Profile Report

Feb. 5 Financial Quick Takes: Aimmune gets $200M Nestlé investment; plus Vineti, MaaT, Kezar, Ziopharm, Ikarovec

$200M for Aimmune as it expands allergy pipeline
Nestlé Health Science made a $200 million equity investment in Aimmune Therapeutics Inc. (NASDAQ:AIMT), giving it a 19.9% stake in the allergy company based on its outstanding common shares. Also on Wednesday, Aimmune licensed exclusive,

Read the full 423 word article

How to gain access

Continue reading with a
two-week free trial.